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ABSTRACT: The current study aimed to evaluate the etomidate anesthetic action, its toxicity profile and safety alone 
and to determine the benefit of xylazine coadministration to enhance its anesthetic duration, efficacy and to reach a 
state of balanced anesthesia in chicks. By using the up-and-down technique, it was found that the hypnotic Median 
Effective Dose (ED50) of the etomidate was 4.30 mg/kg, IM, whereas the acute Median Toxic Dose (TD50) was 17.90 
mg/kg, IM in the chicks. In response, the calculated Therapeutic Index (TI) and Standard Safety Margin (SSM) indicate 
that the etomidate has a wide safety margin. Etomidate injection at 4, 8 and 16 mg/kg, IM yields a significant dose-re-
sponse and dependent hypnosis in the chicks by evaluating the onset of the righting reflex loss, its period and regaining 
from it. The combination composed of etomidate and xylazine at 5 mg/kg, IM for each, reduced the onset of hypnosis 
and significantly distended its period besides a significant rise of the recovery time when compared with the group 
receiving etomidate alone. At the same time, this coadministered drugs elicited a significant raise in analgesic efficacy. 
Concerning plasma glucose, Alanine Transaminase (ALT) and Aspartate Transaminase (AST) concentrations, neither 
etomidate nor etomidate plus xylazine differ significantly from the control group. The results of this study propose the 
likelihood of using etomidate as an anesthetic agent for short surgical trials in the chickens that can be more effective 
by using xylazine to yield balanced anesthesia without causing significant side effects.
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Etomidate is an imidazole derivative that belongs to non-barbiturate anesthetics acting as a short 
anesthetic agent used for rapid induction of gener-
al anesthesia. The mechanism by which etomidate 
induced anesthesia via its potentiation of the neu-
rotransmitter Gamma Aminobutyric Acid (GABA) 
and tighten its binding to GABAA receptor, leading 
to depression of the central nervous system (Finkel 
et al., 2009; Forman, 2011). Etomidate has a good 
hypnotic effect but less analgesic and muscle relax-
ation efficacy with little to negligible effect on the 
cardiovascular system (unlike ketamine) so it is used 
for cardiac and vascular surgeries (Finkel et al., 2009; 
White and Trevor, 2009; Forman, 2011). Etomidate 
has a side effect by maintaining the sympathetic out-
flow (Ebert et al., 1992) besides the suppression of the 
adrenal gland cortex (Jabre et al., 2009) and causing 
cognitive deficits as found in a rat model (Dixon et 
al., 2003). Furthermore, xylazine considered to have 
analgesic and sedative effects as well as muscle relax-
ant effect which results from its action by stimulating 
α2–adrenoceptor causing an inhibition of the release 
of noradrenaline neurotransmitter and leading to de-
pression of the central nervous system. Xylazine is 
used commonly with ketamine to produce balanced 
anesthesia characterized by good hypnotic, analgesic 
and muscle relaxant effects (Pawson, 2008; Kleinz 
and Spence, 2008). 
The main goal of this study was to evaluate the 
anesthetic profile of etomidate (as well as its toxic-
ity and safety) in the chickens and to determine the 
benefit of xylazine coadministration to enhance its an-
esthetic duration, efficacy and to reach a state of bal-
anced anesthesia which is characterized by good hyp-
nosis, analgesia, muscle relaxation and hyporeflexia. 
The above goal is of a major outcome to be applied 
in the surgical operations and may be substituted the 
ordinary protocol of ketamine-xylazine combination 
in animals since the latter combination lack the com-
plete criteria of balanced anesthesia with the presence 
of cardiovascular side effect of ketamine.
MATERIAL AND METHODS
Birds
7-14 days-old chicks (70 overall chicks were used 
in this study) of both sexes were used in all the ex-
periments with mean body weights between 0.1–0.15 
kg. They retained in 25 chicks per cage at 30–33○C 
of temperature (which is the optimal temperature at 
this age of chicks) besides incessant light and the litter 
made up of wood shreds. The birds’ advent to water 
and food at will. The dose of etomidate (Hypnomidate 
0.2%, Janssen-Cilag Ltd., UK) and xylazine (2%, al-
fasan, Holland) were diluted with a physiological nor-
mal saline solution in 10 ml used to make the desired 
concentration to be injected in the chicks for each kg 
of bird mass as intramuscularly (IM) route (10 ml/
kg, IM). 
For ethical respects, the professional scientific 
committee of the department of physiology, biochem-
istry and pharmacology / College of the Veterinary 
Medicine / University of Mosul agreed and permitted 
this research for the necessarly utilization of optimal 
experimental animals.
Determination of the hypnotic ED50 of etomidate 
in chicks
Hypnotic ED50 value of etomidate was estimated 
conferring to the up and down mode (Dixon, 1980). 
First etomidate’s dosage of 5 mg/kg, IM depends on 
an introductory study. The chicks were superintend-
ed for two hours to the incidence of the etomidate’s 
hypnosis (lack the righting reflex). The doses of eto-
midate then would be diminished or augmented 1 mg 
rely on the incidence or absence of the hypnotic effect 
in the chicks, respectively (Mousa and Al-Zubaidy, 
2019). The ED50 value was calculated as follows:
ED50 value = xf + K d  were:
xf = The last dose used
K = Table’s value which extracted from Dixon, 1980 
(depend on X and O symbols obtained)
d = ± in the dosage 
The marks elicited by etomidate hypnosis in 
chicks (during 1-2 min.) were ataxia, recumbency, 
closed eyelids, loss of righting reflex and the hypnosis 
characterized by quiet sleep.
Evaluation of acute TD50 of etomidate in chicks
This experiment was conducted also conferring 
the up and down described before (Dixon, 1980) men-
tioned above. Rudimentary dosage of etomidate at 20 
mg/kg, IM which depends on an initiative procedure. 
The chicks were watched twenty-four hours aimed at 
the appearance of etomidate’s toxic marks thereafter, 
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the doses of etomidate should be reduced or amplified 
3 mg according to the death presented by etomidate in 
the chicks. The TD50 was calculated from the equation 
in the same manner as previous experiment.
The toxicity signs observed in the chicks were re-
cumbency, defecation, excitation, paralysis, increased 
sensitivity to external stimuli, an increase in the wings 
and leg movements and the outcome was death during 
4-8 min.
Estimation of the drug safety indices of etomidate
The ED50 and TD50 values of etomidate mentioned 
above were used for the interpretation and extrapola-
tion the drug safety of etomidate through its use in the 
following equations (Muller and Milton, 2012):
TI = TD50 \ ED50 (The higher the number of TI re-
sulted in means that the drug is safe and vice versa). 
SSM = (TD1 \ ED99 – 1) × 100 (TD1 is the mini-
mum dose which produces an adverse effect in 1% 
of the experimental sample and ED99 is the minimum 
dose required to produce the therapeutic effect in 99% 
the experimental sample; large SSM value means the 
drug is safer).
The dose-responsive hypnotic effect of etomidate 
in chicks
Etomidate’s hypnosis (lack the righting reflex) 
were watched in three groups of chicks (six chicks/
dose group) that injected with different doses of eto-
midate at 4, 8 and 16 mg/kg, IM procured from the 
hypnotic ED50 value of etomidate from the previous 
experiment in chicks. The onset of hypnosis (indicat-
ed by the loss of the righting reflex) was calculated as 
the time from etomidate injection to the loss of right-
ing reflex. The duration of hypnosis is the time from 
the loss of the righting reflex till the chick return and 
corrected their body to normal position while the re-
covery time was defined as the time between the onset 
of hypnosis until the chick begin to move and restore 
the normal activity (Roder et al., 1993; Mousa and 
Al-Zubaidy, 2019).
Hypnotic and analgesic efficacy of etomidate and 
the effect of xylazine combination in chicks
A. Effect of xylazine on etomidate hypnosis
Two groups of chicks (6 chicks/group) were used, 
the first one consisted of etomidate injection alone 
at 5 mg/kg, IM and the second one composed of in-
jection of etomidate and xylazine at 5 mg/kg, IM for 
each drug. The dose of etomidate was selected from 
the previous two experiments while the dose of xyla-
zine was selected from another study as it resembles 
the effective dose of xylazine in the chicks (Mousa 
and Mohammad, 2012a; Mousa et al., 2019). Onset, 
duration and recovering from hypnosis were written 
down in two groups for every chick individually.
B. Effect of xylazine on etomidate analgesia
Other chickens of the same groups mentioned 
above composed of etomidate alone or etomidate plus 
xylazine were used in this trial. The voltage of elec-
tro-stimulator device (Harvard apparatus, USA) that 
induce nociceptive effect (specified by distress call) 
was recorded pre- and post-5 minutes of therapy. The 
proportion of analgesic effect (the number of chicks 
that show analgesia to total), its volts including volt-
age (delta) for every group was also noted (Mousa and 
Mohammad, 2012b; Mousa, 2014; Mousa, 2019a).
Measurement of plasma glucose, ALT and AST 
concentrations in the chicks treated with etomi-
date alone or etomidate plus xylazine
After 2 hours of etomidate injection alone (5 mg/
kg) or etomidate plus xylazine (5 mg/kg, IM for both 
drugs), the blood got from the jugular vein of the 
neck (6 chicks/group), experiencing centrifugation 
to gain the plasma which refrigerated pending analy-
sis during 48 hours. The procedure for estimation of 
glucose concentration (Wotton, 1974), AST and ALT 
(Yang et al., 2018) concentrations in plasma were an-
alyzed for all the groups mentioned earlier, in addition 
to the –ve saline control which all analyzed with the 
specified kit (Biolabo, France) for glucose and liver 
enzymes by mean of Chemistry Analyzer Smart-150 
apparatus (GenoTEK, USA).
Statistical analysis 
Parametric data (onset, duration and recovery 
from hypnosis as well as glucose, ALT and AST con-
centrations of three groups) were analyzed by analy-
sis of variance (one-way) followed by the LSD, while 
student T-test implemented to analyze the two groups 
(onset, duration and recovery from the hypnosis of 
two groups besides the pre and post-voltage recorded) 
(Katz, 2011; Petrie and Watson, 2013). The non-para-
metric outcome (% antinociception) were resolved by 
the Fisher exact probability and Mann-Whitney-U-
test (delta voltage)(Kvam and Vidakovic, 2007; Katz, 
2011). The outcome reflected significantly differs 
once p was < 0.05.
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Hypnotic ED50 value for etomidate in chicks
The ED50 value of etomidate that generates hypno-
sis (lack the righting reflex) in 50 % of the subjected 
chicks was at 4.30 mg/kg, IM as resolved by the up 
and down technique (Table 1). 
Table 1. Etomidate’s hypnotic ED50 in the chicks
ResultParameter
4.30 mg/kg, IMED50 value = xf + K d
4-5 mg/kgThe extent of the doses applied
5 mg/kgStarting dose
5 mg/kgEnding dose (xf)
1 mg± in the dosage (d) 
5 (XOXOX)*Chicks used
1-2 minutesStarting of hypnosis
X: effect (hypnosis), O: no effect (no hypnosis)
*: Symbols (XOXOX) used to extract table value (K) from 
Dixon, 1980
Acute TD50 for etomidate in experimental chicks
Table 2 exhibits acute etomidate’s TD50 value in 
chicks determined to became 17.90 mg/kg, IM. 
Table 2. Determination of acute TD50 of etomidate in chicks 
ResultParameter
17.90 mg/kg, IMAcute TD50 value = xf + K d
17-20 mg/kgThe extent of the doses applied
20 mg/kgStarting dose
20 mg/kgEnding dose (xf)
3 mg± in the dosage (d) 
5 (XOXOX)*Chicks used
4-8 min.Occurence of death
X: effect (death), O: no effect (alive)
*: Symbols (XOXOX) used to extract table value (K) from 
Dixon, 1980
Drug safety of etomidate as estimated by safety in-
dices
By using the values of ED50 and TD50 of etomidate 
mentioned above, The TI of etomidate estimated will 
be 4. 
TI = TD50 \ ED50  = (17.90 mg/kg) \ (4.30 mg/kg) = 
4.16 = approximate to 4 
The TI number (4) means that the effective dose 
(ED50) used of etomidate should be multiplied 4 times 
to induce the toxic effect of etomidate and kill 50% of 
the animals (TD50). 
In contrast, The SSM estimated from its equation 
is as follows:
SSM = (TD1 \ ED99 – 1) × 100 = (0.358 mg/kg \ 
8.514 mg/kg – 1) × 100 = 100 % (The TD1 and ED99 
values were calculated in response to TD50 and ED50 
values respectively mentioned above).
The SSM calculated (100%) means that the effec-
tive dose of etomidate (ED99) that produces 99 % an-
esthesia in animals should be increased by 100% (i.e. 
from 8.514 to 17.028 mg/kg, IM) to kill 1% of the 
animals (TD1) and produces its toxic and deleterious 
effects. Thus the TI and SSM values reflect that eto-
midate possesses a preferable and had a wide margin 
of safety.
The dose-response hypnotic effect of etomidate in 
chicks
 Etomidate injection at 4, 8 and 16 mg/kg, IM pro-
duces significant narcosis as dosage hooked-on mode. 
Hypnotic onset (which is the lack of righting reflex) 
was fast during 1-5 min. while the period of hypnosis 
was short between 18-43 min. as well as the regaining 
from the hypnotic effect of etomidate lasts for 28-84 
min. which depend on the doses of etomidate (Table 
3).
Table 3. Hypnosis (dose-response) of multiple etomidate dosages 
in chicks 
HypnosisEtomidate 
(mg/kg, IM) Recovery (min.)Duration (min.)Onset (min.) 
28.67 ± 2.00 18.00 ± 1.655.67 ± 1.15  4
43.83 ± 1.90 *27.67 ± 2.25 * 1.33 ± 0.21 *  8
84.00 ± 6.04 *,a 43.83 ± 1.89 *,a 1.00 ± 0.00 *  16
The values typify Mean ± Std.E. for 6 chicks per dose group of 
chicks
*: significantly difference (p < 0.05) from etomidate dosage 4 
mg/kg, IM 
a: significantly difference (p < 0.05) from etomidate dosage 8 
mg/kg, IM 
Effect of xylazine on anesthetic efficacy of etomi-
date in chicks
A. The Effect of xylazine on hypnosis produced by 
etomidate 
The combination composed of etomidate at 5 mg/
kg, IM and xylazine at the same dose, shortened the 
onset of hypnosis and significantly prolong its period 
as well as there was a significant increase in the re-
gaining time from the hypnotic effect when compared 
with the group that receives etomidate alone (Table 
4-A). 
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Table 4-A. Etomidate’s hypnotic effect alone or with xylazine in chicks 
Hypnosis
Groups
Recovery (min.)Duration (min.)Onset (min.)
51.33 ± 2.93 32.67 ± 1.91 1.67 ± 0.33  Etomidate alone(+ve control)
86.83 ± 4.82 * 59.00 ± 2.93 * 1.00 ± 0.00  Etomidate and xylazine
The values typify Mean ± Std.E. for 6 chicks per group of chicks
Etomidate treatment at 5 mg/kg, IM with or without xylazine at 5 mg/kg, IM
*: significantly difference (p < 0.05) from etomidate alone
B. The Effect of xylazine on analgesia produced by 
etomidate 
The 5 min. recording of the analgesic effect pre-in-
jection of etomidate and xylazine combination de-
notes that there was a significant increase in the ant-
inociceptive efficacy in comparison to the group that 
treated with etomidate alone. At a similar moment, a 
significant rise in the proportion of analgesic efficacy 
and a significant increase in the voltage (delta) that 
produces nociception in comparison to the group that 
injected with etomidate alone (Table 4-B). 









5.00 ± 2.42 11.00 ± 2.65  6.00 ± 0.45  50Etomidate alone(+ve control)
16.00 ± 1.06 * 23.00 ± 0.82 *,+ 7.00 ± 0.52  100 *Etomidate and xylazine
The values typify Mean ± S.E. for 6 chicks per group of chicks
Nociception induced by electro-stimulation (registered pre- and post 5 minutes) of etomidate therapt (5 mg/kg, IM) with or without 
xylazine (5 mg/kg, IM)
*: significantly difference (p < 0.05) from etomidate alone 
+: significantly difference (p < 0.05)  as of volts (pre-treatment) in the same group of chicks
Determination of plasma glucose, ALT and AST 
concentrations in the chicks treated with etomi-
date alone or etomidate plus xylazine
Table 5 revealed that there is no significant differ-
ence in plasma glucose, ALT and AST concentrations 
between groups that received normal saline (-ve con-
trol), etomidate alone (+ve control) and that treated 
with etomidate plus xylazine at 5 mg/kg, IM for each 
drug. 
Table 5. Plasma glucose, ALT and AST concentrations in chicks treated with etomidate alone or etomidate plus xylazine
AST (U/L)ALT (U/L)Glucose concentration
 (mg/dl)
Groups
114.00 ± 5.51 15.35 ± 2.10  133.32 ± 11.93 Normal saline 
(-ve control)
104.10 ± 4.71 18.37 ± 2.19  135.67 ± 14.97 Etomidate alone
(+ve control)
111.73 ± 2.55 14.93 ± 1.12  142.67 ± 10.24 Etomidate and xylazine 
The values typify Mean ± Std.E. for 6 chicks per group of chicks
Etomidate and xylazine were injected at 5 mg/kg, IM for each drug
http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 23/08/2021 05:34:46 |




The main goal of this study was to evaluate the 
anesthetic profile of etomidate in the chickens and to 
determine the benefit of xylazine coadministration to 
enhance its anesthetic duration, efficacy and to reach 
a state of balanced anesthesia which is characterized 
by good hypnosis, analgesia, muscle relaxation and 
hyporeflexia. The mentioned goal is of a major and 
valuable outcome to be applied in the surgical oper-
ations and may be substituted the ketamine-xylazine 
combination in animals since the latter combination 
lack the complete criteria of balanced anesthesia 
with the presence of cardiovascular side effect of ket-
amine. Etomidate is considered a general anesthetic 
agent that produces rapid induction with a short du-
ration of anesthesia by its potentiation of the GABA 
neurotransmitter and GABAA receptor effect, causing 
an inhibition of the nervous system. Etomidate has a 
good hypnotic effect but less analgesic and muscle 
relaxation efficacy with little to negligible effect on 
the heart and circulation so it is used for cardiovas-
cular surgeries (Finkel et al., 2009; White and Trevor, 
2009; Forman, 2011) though, etomidate is considered 
a safe drug of choice for using in anesthesia in human 
because it possesses many advantages including a 
well-known mechanism, protection from myocardial 
and cerebral ischemia, decreasing histamine release 
with a uniquely stable hemodynamic status (Bergen 
and Smith, 1997; Vinson and Bradbury, 2002; Falk 
and Zed, 2004; Forman, 2011), has a neuroprotective 
efficacy on the nervous system in contradiction of the 
diabetic oxidative injury (Ates et al., 2006) and was 
found to have efficient anesthesia than pentobarbital 
(Baxter et al., 2007). In response, the values of TI 
and SSM calculated in this study refers that the eto-
midate is safe and possesses a wide margin of safety 
(Janssen et al., 1975; Forman, 2011). Furthermore, 
xylazine preferred to use commonly with anesthetic 
agents like ketamine to produce balanced anesthe-
sia characterized by worthy hypnosis, analgesic and 
muscle relaxant properties because it possesses anal-
gesic, sedative, and muscle relaxant efficacy that are 
resultant from nits action on α2–adrenoceptor (Paw-
son, 2008; Kleinz and Spence, 2008). The result of 
this study clarifies the anesthetic profile of etomidate 
in the chicks through determining the hypnotic ED50 
and acute TD50 values as well as by evaluating the 
hypnotic dose-response fashion for etomidate which 
came close and in accordance to what’s found in other 
laboratory animals (Janssen et al., 1975). As found in 
this study, etomidate when combined with xylazine, 
produce balanced anesthesia. That etomidate-xyla-
zine combination enlarged the hypnotic effect and 
increased the analgesic efficacy as well as a decrease 
in the doses of both agents with minimizing the side 
effects of both drugs when compared with etomi-
date alone and it is typically of beneficial value for 
use in surgeries and may replace the classical rem-
edy of ketamine-xylazine combination. The interac-
tion between etomidate and xylazine may be regard-
ed as their synergistic inhibition of the various areas 
of the brain with different mechanisms of action on 
their receptors. Xylazine alone was known to cause 
an increase in plasma glucose concentration, as a side 
effect, due to its mechanism of action (Roder et al., 
1993). Neither etomidate alone, nor etomidate plus 
xylazine differ significantly from the negative control 
(saline group) concerning plasma glucose, ALT and 
AST concentrations as showed in this study that came 
close to the normal concentration ranges in chickens 
of another study (Cruz et al., 2018) and the reason 
may be attributed to their single and small doses of 
each drug used for a short period of time and the short 
time for plasma estimated suggesting another reason 
for using this combination for inducing prolonged an-
esthesia in the chicks.
CONCLUSIONS
The results of this study propose the likelihood of 
using etomidate as an anesthetic agent for short surgi-
cal trials in the chickens that can be more effective by 
using xylazine to yield balanced anesthesia (charac-
terized by good hypnosis and analgesia) without caus-
ing significant side effects; supplementary studies are 
required in other animal species.
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